<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102710">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149160</url>
  </required_header>
  <id_info>
    <org_study_id>FRM-0334-002</org_study_id>
    <secondary_id>2014-001489-85</secondary_id>
    <nct_id>NCT02149160</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FORUM Pharmaceuticals Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>France: Ministry of Health</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to investigate the safety, tolerability, and pharmacodynamics
      of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin
      mutation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of FRM-0334</measure>
    <time_frame>Baseline to Day 28 or Early Termination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number and percentage of subjects with AEs
Number and percentage of subjects with SAEs
Number and percentage of subjects who discontinue due to AEs
Number and percentage of subject deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the pharmacodynamic (PD) effects of FRM-0334 on the change from baseline in plasma concentrations of progranulin (PGRN) after 28 days</measure>
    <time_frame>Baseline to Day 28 or Early Termination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effects of FRM-0334 on the change from baseline in cerebrospinal fluid (CSF) concentrations of PGRN after 28 days</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in CSF progranulin concentration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the plasma concentrations of FRM-0334 and metabolites following once daily dosing for 28 days</measure>
    <time_frame>Day 1 to Day 28 or Early Termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Ctrough, tmax, t1/2, λz, AUC(0-τ), CL/F, Cav in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the CSF concentrations of FRM-0334 and metabolites following once daily dosing for 28 days</measure>
    <time_frame>Day 1 to Day 28 or Early Termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Ctrough, tmax, t1/2, AUC0-τ, CL/F, Cav in CSF</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Granulin Mutation</condition>
  <arm_group>
    <arm_group_label>FRM-0334; Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose, Capsule, Once Daily, Day 1 through Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FRM-0334; Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose, Capsule, Once Daily, Day 1 through Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator; Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Capsule, Once Daily, Day 1 through Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FRM-0334</intervention_name>
    <arm_group_label>FRM-0334; Arm 1</arm_group_label>
    <arm_group_label>FRM-0334; Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator; Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ages aged ≥21 and ≤75 years

          -  Genotyped positive for a FTD-GRN mutation, and aware of it

          -  Prodromal to moderate FTD-GRN

          -  Resides in a stable living situation, living at home, senior residential setting, or
             an institutional setting without the need for continuous (ie, 24-hour) nursing care

          -  Proficiency (oral and written) in the language in which study-related documents,
             including the ICF and  standardized tests, will be administered

          -  Able to swallow capsules

          -  Be in good general health, willing and able to comply with the protocol requirements,
             and expected to complete the study as designed (in the judgment of the investigator)

        Exclusion Criteria:

          -  Clinically significant abnormalities on physical examination, medical history,  ECG,
             vital signs, laboratory values, or unstable medical or psychiatric illness

          -  Females who are pregnant, breastfeeding, or planning to become pregnant during the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carla Keefe</last_name>
    <phone>617-225-4289</phone>
    <email>ckeefe@forumpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histone deacetylase inhibitor</keyword>
  <keyword>Frontotemporal dementia</keyword>
  <keyword>Granulin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
